On October 5, 2023, an important study, published in JAMA and authored by Mohit Sodhi, indicated an increased risk of gastroparesis, bowel obstruction, and pancreatitis for those using GLP-1 agonists
In plain terms, even if your body has developed some degree of resistance to GLP-1 signaling, the GIP pathway and the biased signaling properties of tirzepatide can still drive insulin response
Sources Enjoying this article
Tirzepatide is injected subcutaneously (under the skin) rather than taken by mouth, which means stomach contents and meal timing do not affect how your body absorbs the medication
Combining them is not experimental
A real workup matters, the kind we build into functional medicine care rather than a five-minute video visit